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NorM, a putative efflux pump of Vibrio cholerae, is a member of the multidrug and toxic compound extrusion
family of transporters. We demonstrate that NorM confers resistance to norfloxacin, ciprofloxacin, and
ethidium bromide. Inactivation of norM rendered V. cholerae hypersensitive towards these fluoroquinolones.
Multiple sequence alignment of members of its family identified several regions of high sequence conservation.
The topology of NorM was determined using -lactamase and chloramphenicol acetyltransferase fusions. The
amino acid residues G184, K185, G187, P189, E190, G192, and G195 in the periplasmic loops and L381, R382, G383,
Y384, K385, and D386 in the cytoplasmic loops, as well as all the acidic and cysteine residues of NorM, were
mutated. Mutants G184V, G184W, K185I, P189S, E190K, and E190A lost the norfloxacin resistance-imparting
phenotype characteristic of NorM. Mutants E124V, D155V, G187V, G187R, C196S, Y384H, Y384S, and Y384F
exhibited partial resistance to norfloxacin. Mutants with replacements of G184 or G187 by A, K185 by R, and E190
by D retained the norfloxacin resistance phenotype of NorM. Analysis of the accumulation of norfloxacin in
intact cells of Escherichia coli expressing NorM or its mutants in the presence or absence of carbonyl cyanide
m-chlorophenylhydrazone supported the results obtained through susceptibility testing and argued in favor of
NorM-mediated efflux as the determining factor in norfloxacin susceptibility in the genetically manipulated
strains. Taken together, these results suggested that E124, D155, G184, K185, G187, P189, E190, C196, and Y384 are
likely involved in NorM-dependent norfloxacin efflux. Except for D155, C196, and Y384, all of these residues are
located in periplasmic loops.
Multidrug efflux pumps extrude a variety of structurally un-
related drugs from cells (3, 23, 30), and pumps such as AcrAB
have been associated with the intrinsic reduced susceptibility of
organisms such as Proteus mirabilis to certain drugs (26, 27, 37).
A family of multidrug efflux proteins has been identified which
utilize the electrochemical potential of Na transport across
membranes as the driving force (8, 21, 24, 25, 34) and which
show sequence similarity. These transporters constitute the
multidrug and toxic compound extrusion (MATE) family,
which contains more than 30 proteins present in all three king-
doms (7), including NorM proteins from Vibrio parahaemolyticus
(21), Neisseria gonorrhoeae, Neisseria meningitidis (27), and Bru-
cella melitensis (4); YdhE, a NorM homologue in Escherichia
coli (21); VmrA from V. parahaemolyticus (8); VcmB, VcmD,
VcmH, VcmN, VcmA, and VcrM of non-O1 Vibrio cholerae (2,
24); PmpM of Pseudomonas aeruginosa (11); and BexA of
Bacteroides thetaiotaomicron (20).
Recently, quinolone resistance was reported for clinical iso-
lates of V. cholerae from Calcutta, India (10). In our laboratory,
we have demonstrated that an efflux pump-dependent mecha-
nism imparts fluoroquinolone (FQ) resistance to clinical iso-
lates of V. cholerae (1), making it important to understand the
mechanism of action of FQ-specific pumps.
Chromosome I of V. cholerae encodes a putative counterpart
of NorM (12) that has a high level of sequence similarity (Fig.
1) to the NorM protein of V. parahaemolyticus. In this report,
we demonstrate that disruption of the norM gene of V. cholerae
confers sensitivity towards fluoroquinolones, making it likely
that NorM is one of the FQ resistance-determining efflux
pumps of this organism. Otsuka et al. (29) have only recently
demonstrated that three conserved acidic residues in the pre-
dicted transmembrane region of NorM of V. parahaemolyticus
are involved in the Na-dependent drug transport process.
However, no detailed information is available on the topology
of this transporter or the role of conserved residues in the
periplasmic and cytoplasmic loops of NorM in FQ efflux. With
this in view, we have carried out a detailed mutational and
topological analysis of V. cholerae NorM, with the particular
aim of identifying residues crucial for imparting FQ resistance.
We focused on residues conserved in the MATE family of
transporters, particularly acidic residues, and determined the
effects of mutating these residues on the norfloxacin (NOR)
sensitivity of the resulting transformants. Our results demon-
strate the importance of E124, G184, K185, G187, P189, and E190,
which are located in periplasmic loops, of D155 and Y384, which
are located in cytoplasmic loops, and of C196, which is located
in a transmembrane segment (TMS), in the norfloxacin resis-
tance-imparting property of NorM.
MATERIALS AND METHODS
Bacteria and growth. The clinical isolate V. cholerae AM54, (1), V. cholerae
N16961, and Escherichia coli TG1acrAB (a gift from K. Nishino, Osaka Uni-
versity, Osaka, Japan) (28) were used in this study. Cells were grown in Luria
broth (LB) at 37°C. Cell growth was monitored by measuring the optical density
at 600 nm.
* Corresponding author. Mailing address: Department of Chemis-
try, Bose Institute, 93/1 Acharya Prafulla Chandra Road, Kolkata
700009, India. Phone: 91 3323506619. Fax: 91 3323506790. E-mail:
manikuntala@vsnl.net.
† Supplemental material for this article may be found at http://aac
.asm.org/
 Published ahead of print on 5 September 2006.
3717
 o
n
 January 7, 2017 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
Chemicals. Ampicillin, NOR, streptomycin, erythromycin, doxorubicin, novo-
biocin, and carbonyl cyanide m-chlorophenylhydrazone (CCCP) were purchased
from Sigma Chemical Co. Kanamycin, tetracycline, and chloramphenicol were
purchased from Roche Applied Sciences, Germany. Ciprofloxacin (CIP) was a
gift from Ranbaxy Laboratories, India. Ethidium bromide (EtBr) was purchased
from Stratagene.
Molecular biological procedures. Standard procedures for cloning, analysis of
DNA, PCR, and transformation were used (32). Enzymes used to manipulate
DNA were obtained from Roche Applied Sciences. All constructs made by PCR
were sequenced to verify their integrity. Kanamycin was used at a concentration
of 50 g/ml, and ampicillin was used at a concentration of 100 g/ml.
The norM gene was amplified from genomic DNA of V. cholerae AM54, using
the primer pair 5-ATGCTAGCTTGGAGAACTCTGTGCATCGTT-3 (sense)
and 5-ATGAATTCTTATGCTGCAAGGTGTAACTGTACG-3 (antisense),
containing asymmetric NheI and EcoRI sites (in bold), and cloned between the
NheI and EcoRI sites of the vector pET28a (Novagen) to generate pVC101. The
NcoI and EcoRI fragment excised from pVC101 was then cloned between
the NcoI and EcoRI sites of the vector pBADHisC (Novagen) to generate pVC102.
Mutants of NorM were generated by overlap extension PCR. The initial
rounds of PCR were carried out using the primer pairs a-b and c-d (see Table S1
in the supplemental material), with pVC102 as the template. The products of
each PCR were purified and used as templates for the second round of PCR,
using primers a and d. The final products were cloned between the NcoI and
EcoRI sites of pVC102 to generate norM mutants in pBADHisC.
Western analysis of expressed protein. E. coli cells transformed with pVC102
or its mutants were grown to mid-log phase, and crude cell extracts were sepa-
rated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, fol-
lowed by electrophoretic transfer to a polyvinylidene difluoride membrane and
Western blotting with an anti-His antibody.
Construction and analysis of -lactamase fusions with truncated NorM de-
rivatives. pJBS633 (carrying the mature TEM -lactamase-encoding blaM gene)
(5) was used for constructing in-frame fusions of TEM -lactamase with the
C-terminal ends of truncated NorM derivatives. These derivatives were gener-
ated by PCR using the forward primer 5-TTGGATCCAATTGGAGAACTCT
GTGCATCGT-3, containing a BamHI site (in bold), and reverse primers car-
rying portions of the norM gene (see Table S2 in the supplemental material). The
FIG. 1. Multiple alignment of the amino acid sequence of NorM with those of representative homologs in Vibrio parahaemolyticus (Vp), Vibrio
cholerae (Vc), Neisseria meningitidis (Nm), and Escherichia coli (Ec), using CLUSTAL W. *, identical residues; :, 60% homologous residues. The
conserved regions G184KFGXP189 and L381RGYKD386 are overlined.
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PCR products were cloned between the BamHI and PvuII sites of pJBS633. E.
coli JM105 was transformed with the ligation mixture, and transformants growing
on LB agar plates containing 50 g/ml kanamycin were chosen for further
analysis. Transformants containing in-frame NorM–-lactamase fusions were
detected by the ability to grow when patched with toothpicks onto agar contain-
ing 200 g/ml ampicillin (6). MICs of ampicillin for individual cells of E. coli
JM105 containing NorM-Xaa–TEM -lactamase fusions (where Xaa represents
the amino acid residue of NorM at the fusion junction) were determined by
spotting 4-l samples of 1:105 diluted overnight cultures (approximately 40 cells)
on LB agar plates containing a range of doubling concentrations of ampicillin.
Construction and analysis of targeted CAT fusions. The cat gene was PCR
amplified from pACYC184, using the forward primer 5-AGGGTACCAAAAA
AATCACTGGATATA-3 (KpnI site is shown in bold) and the reverse primer
5-ATAAAGCTTCGCCCCGCCCTGCCACTC-3 (HindIII site is shown in
bold), and inserted between the KpnI and HindIII sites of pBADMycHisA,
generating pBAD-CAT. Chloramphenicol acetyltransferase (CAT) construc-
tions were created by targeted PCR fusion with derivatives of NorM, inserting
KpnI sites after the amino acids of interest by using the forward primer 5-AT
ACTGCAGATTTGGAGAACTCTGAG-3, containing a PstI site (in bold), and
reverse primers (see Table S2 in the supplemental material) carrying portions of
the norM gene. The constructs were transformed into E. coli TG1 containing 100
g/ml ampicillin and tested for resistance to chloramphenicol as follows. Over-
night cultures in LB medium were diluted 10-fold with fresh medium and allowed
to grow for 3 h. Induction was then carried out by the addition of 0.05%
L-arabinose for 1 h, and 4-l samples of a 104 dilution of the cultures were
spotted onto plates containing different concentrations of chloramphenicol in
combination with 0.2% L-arabinose. Growth was observed after 16 h.
Drug susceptibility testing. The MICs of drugs were determined in Mueller-
Hinton agar (Hi-Media, India) containing different drugs at various concentra-
tions. E. coli TG1acrAB cells transformed with the wild-type or mutant norM-
harboring constructs were grown at 37°C in LB supplemented with ampicillin
(100 g/ml) to an optical density at 600 nm of 1. A series of 10-fold dilutions were
spotted on plates containing ampicillin (40 g/ml) and different concentrations
of test drugs (38), and growth was observed after 16 h.
Assay of norfloxacin accumulation in cells. The assay of norfloxacin accumu-
lation in cells was carried out as described earlier (1). Briefly, E. coli TG1acrAB
cells were grown in LB supplemented with 100 g/ml ampicillin to an A600 of 1.
The cells were harvested, washed with 50 mM sodium phosphate buffer (pH 7.2),
and suspended in the same buffer to an A600 of 20. Cells were energized with
0.2% glucose for 20 min at 30°C. Norfloxacin was added to a concentration of 10
g/ml. Where necessary, after 10 min, CCCP was added to the assay mixture at
100 M. Samples (100 l each) were taken at intervals, centrifuged at 6,000 rpm
on a table-top centrifuge for 30 s, and washed with the same buffer. The pellet
was suspended in 1 ml of 100 mM glycine-HCl buffer (pH 3.0). The suspension
was shaken vigorously for 1 h at 37°C and then centrifuged at 13,000 rpm in a
microcentrifuge for 5 min at room temperature. The fluorescence of the super-
natant was measured with excitation at 277 nm and emission at 448 nm (13, 22)
in a Hitachi spectrofluorimeter (model S4500). For each experiment, an aliquot
of cells was filtered separately, before the addition of norfloxacin, using What-
man GF/C filters. The filters were dried and weighed to calculate the dry weight
of the cells.
Assay of ethidium bromide accumulation in cells. Cells were grown as de-
scribed above and suspended to an A600 of 0.5. The cell suspension (2.5 ml) was
mixed with 5 M ethidium bromide and placed in a cuvette. Fluorescence was
measured at excitation and emission wavelengths of 500 and 580 nm, respectively
(19).
Inactivation of V. cholerae norM. The norM deletion construct was generated
by PCR, using genomic DNA of V. cholerae N16961 as the template. The primer
pair sense 1 (5-ATGAATTCGAGCTCAACATGACAGTTGATGAG-3) and
antisense 1 (5-ATGGTACCGATATTGAGCAATAACCCAA-3), containing
asymmetric EcoRI and KpnI sites (in bold), was used to amplify an 842-bp
fragment (fragment 1) encoding N-terminal amino acids 1 to 175 along with a
300-bp sequence upstream of norM. Similarly, the primer pair sense 2 (5-ATG
GTACCCTTGGCTTGCCCACCGGTTA-3) and antisense 2 (5-ATGGATCC
CCAGTAAGCAGCAAAAGTGC-3), containing asymmetric KpnI and
BamHI sites (in bold), was used to amplify a 433-bp fragment (fragment 2)
encoding amino acids 401 to 461 along with a 250-bp region downstream of
norM. PCR-amplified fragment 1 was cloned between the EcoRI and KpnI sites
of pUC19 to generate pAS101. Fragment 2 was then digested with KpnI and
BamHI and cloned between the same sites of pAS101 to generate pAS102. The
deleted norM gene from pAS102 was digested with BamHI and SacI and cloned
into the suicide vector pWM91 (17; kindly provided by J. J. Mekalanos) between
the same sites to generate pAS103. pAS103 was introduced into recipient V.
cholerae N16961 cells by electroporation (15). Colonies were selected on LB
plates supplemented with streptomycin and ampicillin. The streptomycin- and
ampicillin-resistant colonies were patched on LB agar overnight to allow homol-
ogous recombination between flanking regions of pAS103. Cells were then se-
lected for the ability to form colonies on 5% sucrose to select for excision of the
integrated plasmid (9). Genomic DNAs isolated from the wild type and the
knockout construct of V. cholerae were used for PCR amplification, using primers
sense 1 and antisense 2, to identify the clones harboring the deletion in norM.
PCR products were checked by sequencing.
RESULTS
Drug susceptibility testing in V. cholerae. In order to evalu-
ate the role of norM in V. cholerae, the norM gene was inacti-
vated. PCR amplification using primers for the flanking re-
gions of the norM gene gave products of 1,842 and 1,179 bp for
the wild type and the mutant, respectively (data not shown),
which were sequenced to confirm the inactivation of norM. The
knockout strain (designated NorM-KO) was 10-fold more
sensitive to FQs (Table 1) than the wild type. In addition, the
MIC of ethidium bromide decreased from 512 g/ml for the
wild type to 128 g/ml for NorM-KO.
Drug susceptibility testing in E. coli. In order to evaluate the
contribution of NorM to drug resistance, norM was expressed
in E. coli TG1acrAB, which is hypersensitive to many drugs
due to a deficiency in the major multidrug efflux pump AcrAB
(28). The drug susceptibilities of E. coli TG1acrAB cells har-
boring the vector alone (control) or pVC102 (the vector car-
rying the norM gene) are shown in Table 2. E. coli TG1acrAB/
pVC102 was resistant to norfloxacin (60-fold), ciprofloxacin
(30-fold), and ethidium bromide (16-fold) but not to sparfloxa-
cin, a hydrophobic FQ. We also observed reproducibly low
levels (two- to fourfold) of resistance to streptomycin, eryth-
romycin, kanamycin, and doxorubicin (Table 2). Considering
that the NorM protein of V. cholerae conferred high resistance
to FQs, we designated NorM as an FQ efflux pump. These
studies were repeated in the presence of CCCP (25 M), an
energy uncoupler that has been shown to inhibit the action of
other efflux pumps (26). CCCP reduced the MICs of norfloxa-
cin, ciprofloxacin, and ethidium bromide for E. coli TG1acrAB/
TABLE 1. Susceptibility to and accumulation of fluoroquinolones
in V. cholerae and E. coli strains
Strain
MIC (g/ml)a Accumulation of NOR(g mg1 cell dry wt)b
NOR CIP
Before
addition
of CCCP
After
addition
of CCCP
V. cholerae strains
Wild type (N16961) 0.0156 0.0039 0.031  0.0012 0.394  0.022
NorM-KO 0.001 0.0004 0.331  0.0019 0.415  0.0025
E. coli strainsc
TG1acrAB harboring
pBADHisC (control)
0.016 0.004 0.367  0.009 0.428  0.012
norM wt/pBADHisC* 1 0.125 0.191  0.012 0.436  0.011
norM G187R/pBADHisC* 0.063 0.032 0.298  0.009 0.432  0.009
norM E190K/pBADHisC* 0.016 0.004 0.386  0.011 0.425  0.012
norM G192V/pBADHisC* 0.5 0.125 0.188  0.008 0.433  0.008
a All experiments were carried out thrice with the same results.
b Data are means  standard deviations for three independent determina-
tions.
c *, norM wt/pBADHisC refers to the wild-type norM gene cloned into
pBADHisC, norM G187R/pBAD HisC refers to the mutant norM gene encoding
the G187R mutation cloned into pBADHisC, and so on.
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pVC102, suggesting that NorM is a proton motive force-de-
pendent pump.
Determination of the topology of NorM by analyses of
NorM–-lactamase and NorM-CAT fusions. A model of the
secondary structure of NorM was developed by using the
HMMTOP algorithm (35, 36) (available freely at http://www
.enzim.hu/hmmtop) (Fig. 2). In order to validate the predicted
topology, targeted fusions of NorM were generated with the
N-terminal end of the TEM -lactamase or CAT reporter. E.
coli JM105 had an MIC of 4 g/ml for ampicillin. The NorM
-Xaa–TEM -lactamase transformants, in which Xaa (the
NorM amino acid at the fusion junction) was G41, D47, S52,
R118, E124, K129, G184, P189, G192, G195, P268, V279, R340, E349,
Q351, T412, or K423, had MICs of 200 g/ml or more for
ampicillin, consistent with the view that these fusion sites were
each in the periplasm, since -lactamase fusion proteins can
provide E. coli with ampicillin resistance only if the 
-lactamase moiety is translocated to the periplasm (5). The
cytoplasmic location of amino acids was studied by analyzing
the NorM-Xaa–CAT fusion transformants, in which Xaa (the
NorM amino acid at the fusion junction with CAT) was K17,
Q78, E91, G95, Q148, D155, A163, S218, E228, P247, I300, N319,
Q374, V375, Y384, R393, or Q442. E. coli TG1 harboring these
fusions showed chloramphenicol resistance, consistent with the
view that these fusion sites were each in the cytoplasm, since
CAT fusion proteins can provide E. coli with chloramphenicol
resistance only if CAT is present in the cytosol. Negative
validation of the predicted topology was carried out by analyzing
-lactamase constructs generated by fusion to transmembrane
(C196 and C197) or cytoplasmic (D155 and E228) amino acids as
well as by analyzing CAT constructs fused to transmembrane
(C196 and C197) or periplasmic (D47 and E124) amino acids.
Fusions to D155 or E228 were ampicillin sensitive. Fusions to
D47 or E124 were chloramphenicol sensitive. Fusions to C196 or
C197 were both ampicillin and chloramphenicol sensitive. We
concluded that the experimentally determined topology cor-
roborated the predicted topology depicted in Fig. 2.
Effects of specific mutations in amino acids located in
periplasmic loops on the function of NorM. The motif
G184KFGAP189 is located in the periplasmic loop between
TMS 5 and 6 (Fig. 2) and is conserved among several members
of the MATE family (Fig. 1). Deletion of this conserved region
rendered the mutant NorM (G184-P189) protein highly sus-
ceptible to norfloxacin (Table 3). In order to further identify
important residues in this region, we replaced G184 with valine
or tryptophan. These replacements caused a complete loss of
activity of NorM, as assessed by determining the MIC of nor-
floxacin as well as that of ciprofloxacin for E. coli TG1acrAB
cells harboring the respective plasmids. However, replacement
of G184 with alanine led to the retention of a significant
amount of wild-type activity [“activity,” as referred to in the
following paragraphs, means the ability of the norM-harboring
construct(s) to impart norfloxacin resistance, as assessed by the
MIC]. Valine differs from glycine in being more space-filling
and exhibiting a lower propensity for forming a -turn struc-
ture. Consistent with this, the substitution G184A did not
cause a large change in activity. By the same token, replace-
ment of G187 with arginine or valine significantly reduced the
wild-type activity, whereas replacement with alanine did not
alter the activity. The positively charged lysine at position 185
was essential for NorM activity. Replacement of K185 with
isoleucine, but not with arginine, resulted in a complete loss of
NorM activity (Table 3). A positive charge therefore appeared
necessary at position 185. The P189S mutant completely abol-
ished NorM activity. Replacement of G192 and G195, two other
conserved residues in the predicted periplasmic loop between
TMS 5 and 6, did not alter NorM activity (Table 3).
Effects of replacement of conserved residues in cytoplasmic
loops. The region L381RGYKD386 in the cytoplasmic loop be-
tween TMS 10 and TMS 11 (Fig. 2) is conserved (Fig. 1).
Replacement of L381 with proline, R382 with glycine, G383 with
valine, K385 with isoleucine, and D386 with valine did not alter
the activity of NorM (Table 3). However, replacement of Y384
with phenylalanine, histidine, or serine showed reductions in
FIG. 2. Schematic representation of the predicted secondary struc-
ture of NorM. The 12 transmembrane helices are boxed. The topology
was designed based on the algorithm HMMTOP (31, 32) and was
confirmed by analysis of -lactamase and chloramphenicol acetyltrans-
ferase fusions with the norM gene.
TABLE 2. Susceptibility of norM-harboring E. coli TG1acrAB
to different compounds
Compounda
MIC (g/ml)b
TG1acrAB TG1acrAB/pVC102
NOR 0.016 1
CIP 0.004 0.125
EtBr 2 32
CCCP 32 32
NOR plus CCCP 0.016 0.016
CIP plus CCCP 0.004 0.004
EtBr plus CCCP 1 1
SPX 0.007 0.007
KAN 1 4
TET 0.25 0.25
CHL 1 1
Streptomycin 2 4
Erythromycin 0.5 1
Doxorubicin 8 16
Novobiocin 2 2
Rhodamine 6G 16 16
Acriflavin 2 2
a NOR, norfloxacin; CIP, ciprofloxacin; EtBr, ethidium bromide; SPX, spar-
floxacin; KAN, kanamycin; TET, tetracycline; CHL, chloramphenicol.
b All experiments were carried out thrice with the same results.
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NorM activity corresponding to MICs of 0.125, 0.063, and 0.25
g/ml, respectively (Table 3), indicating that Y384 plays an
important role in NorM activity. Partial retention of activity in
the Y3843S and Y3843F mutants suggested that the -OH
group (common to tyrosine and serine) as well as the phenyl
ring (common to tyrosine and phenylalanine) likely has a bear-
ing on NorM activity. Replacement of Y384 with histidine al-
tered NorM activity, suggesting that a positively charged func-
tional group is not favored at this position. Mutagenesis of
M387, which is not a conserved residue, caused no significant
change in NorM activity.
Effects of replacement of cysteine residues on NorM activity.
There are three cysteine residues in the deduced amino acid
sequence of NorM (Fig. 1), all of which are in transmembrane
segments (Fig. 2). In order to determine whether one of these
cysteines is in a region of functional significance, we analyzed
variants in which NorM cysteines were replaced individually by
serine. In one (C196S) of the three instances, the C3S deriv-
ative displayed an eightfold higher susceptibility than the wild-
type protein, while in the remaining two cases (C330S and
C369S), NorM activity remained unaltered (Table 3). Multiple
alignments identified the cysteine at position 196 of V. cholerae
(Fig. 1) as a conserved residue in 17 NorM homologs (data not
shown).
Effects of replacement of acidic residues on NorM activity.
NorM contains 13 glutamic acid (at positions 2, 11, 91, 123,
124, 190, 228, 237, 255, 308, 341, 349, and 417) and 9 aspartic
acid (at positions 36, 47, 121, 155, 310, 371, 386, 452, and 453)
residues. All of the acidic residues were replaced individually
with valine (Table 3). The activity of each of the mutant pro-
teins was analyzed by drug susceptibility testing. All of the
mutant proteins in which acidic residues were mutagenized
were active enough to sustain a level of resistance practically
identical to that of the wild type, except in the cases of E124,
D155, and E190 mutants. The E124V and D155V substitutions
had partial but significant effects on drug susceptibility. E190,
the only acidic residue in the periplasmic loop between TMS 5
and 6, led to a complete loss of activity when replaced with
either lysine, alanine, or valine. The substitution E190D did
not influence the norfloxacin resistance-imparting phenotype
of NorM, thus highlighting the importance of an acidic residue
at position 190. In order to demonstrate the expression of
mutated proteins in E. coli, Western analysis was carried out
with crude cell extracts and an anti-His antibody. The results
obtained with a representative set of mutants are presented in
Fig. 3. Equal levels of expression were observed for all mutants
compared to the expression level of wild-type NorM, indicating
that decreased expression or instability of the mutant protein
was not responsible for the impaired efflux pump activity in any
case.
Accumulation of norfloxacin in intact cells of V. cholerae and
E. coli. The accumulation of norfloxacin in NorM-KO was
higher than that in the wild-type strain (Table 1). Disruption of
efflux pump activity with CCCP led to the accumulation of
FIG. 3. Western blot analysis of recombinant NorM and its mu-
tants. Wild-type NorM and site-directed mutants (as indicated in the
figure) were expressed in E. coli TG1acrAB as N-terminally His-
tagged proteins. Cell lysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, followed by Western blotting using
an anti-His monoclonal antibody.
TABLE 3. Norfloxacin resistance of E. coli TG1acrAB
expressing mutant NorM proteinsa
NorM mutant NOR MIC (g/ml)
Vector alone ............................................................................0.016
Wild type ..................................................................................1
E2V...........................................................................................0.5
E11V.........................................................................................1
D36V.........................................................................................1
D47V.........................................................................................0.5
E91V.........................................................................................0.5
D121V.......................................................................................0.5
E123V.......................................................................................0.5
E124V.......................................................................................0.063
D155V.......................................................................................0.063
	G184KFGAP189
 ...................................................................0.016
G184V.......................................................................................0.016
G184W......................................................................................0.016
G184A.......................................................................................0.5
K185I ........................................................................................0.0156
K185R.......................................................................................1
G187V.......................................................................................0.25
G187R.......................................................................................0.063
G187A.......................................................................................1
P189S ........................................................................................0.016
E190K .......................................................................................0.016
E190A.......................................................................................0.016
E190V.......................................................................................0.016
E190D.......................................................................................1
G192V.......................................................................................0.5
G195V.......................................................................................1
C196S........................................................................................0.125
E228V.......................................................................................0.5
E237V.......................................................................................0.5
E255V.......................................................................................0.5
G270V.......................................................................................1.0
E308V.......................................................................................0.5
D310V.......................................................................................0.5
C330S........................................................................................1
E341V.......................................................................................0.5
E349V.......................................................................................0.5
C369S........................................................................................1
D371V.......................................................................................0.5
L381P........................................................................................1
R382G.......................................................................................1
G383V.......................................................................................1
Y384F .......................................................................................0.125
Y384H ......................................................................................0.063
Y384S........................................................................................0.25
K385I ........................................................................................0.5
D386V.......................................................................................0.5
M387I........................................................................................1
E417V.......................................................................................0.5
D452V.......................................................................................1
D453V.......................................................................................0.5
a All experiments were carried out thrice with the same results.
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norfloxacin in the parent strain to the level observed in NorM-
KO, suggesting a role for NorM in FQ efflux. These data were
in harmony with the increased sensitivity of NorM-KO to FQs
compared to that of the wild-type strain (Table 1). In addition,
the accumulation of EtBr was higher (1.30  0.0015 g mg1
dry weight of cells) in NorM-KO than in the wild type (0.7 
0.0012 g mg1 dry weight of cells). After the addition of
CCCP, both strains showed similar levels of accumulation of
EtBr (wild type, 1.41  0.0015 g mg1 dry weight of cells;
NorM-KO, 1.37  0.0031 g mg1 dry weight of cells). Nor-
floxacin accumulation was also determined for E. coli
TG1acrAB harboring the vector alone or a vector carrying
wild-type norM or its mutants. The results obtained with a
representative set of mutants are presented in Table 1. These
mutants are as follows: (i) NorM G192V (as resistant as the
wild type), (ii) NorM G187R (partially resistant), and (iii)
NorM E190K (as sensitive as TG1acrAB alone). E. coli
TG1acrAB cells harboring wild-type norM or the G192V mu-
tant showed lower levels of norfloxacin accumulation than cells
harboring the vector alone (Table 1). Accumulation was com-
parable in cells harboring the E190K mutant or the vector
alone. The accumulation of norfloxacin in cells harboring the
G187R mutant was intermediate between the levels observed
in cells harboring the vector alone and those harboring the
G192V mutant. We concluded that the results obtained by
susceptibility testing correlated directly with the levels of nor-
floxacin accumulation in the cells. The addition of CCCP to the
assay mixture increased the accumulation to the level in con-
trol cells (Table 1). These data argue in favor of a role of
proton motive force-dependent, NorM-mediated norfloxacin
efflux in norfloxacin susceptibility in the above instances.
DISCUSSION
Recently, it was reported that NorM, a putative multidrug
efflux protein of the MATE family from V. parahaemolyticus,
confers resistance to hydrophilic FQs, such as norfloxacin and
ciprofloxacin, but not to hydrophobic quinolones, such as spar-
floxacin and nalidixic acid (21). Consistent with this, we report
here that NorM of V. cholerae expressed in E. coli conferred
high-level resistance (10-fold) to norfloxacin, ciprofloxacin,
and ethidium bromide and low-level resistance (2- to 4-fold) to
kanamycin, streptomycin, erythromycin, and doxorubicin. No
resistance was observed towards sparfloxacin, tetracycline,
chloramphenicol, novobiocin, or CCCP (Table 2). We there-
fore concluded that NorM of V. cholerae has functional simi-
larity to NorM of V. parahaemolyticus (21) and NorMI of
Brucella melitensis (4). In the presence of CCCP (25 M), E.
coli TG1acrAB harboring the wild-type norM gene became as
sensitive to norfloxacin, ciprofloxacin, and ethidium bromide
as the strain harboring the empty vector. In addition, E. coli
TG1acrAB harboring the wild-type norM gene showed less
norfloxacin accumulation than the strain harboring the empty
vector. The increase in accumulation upon addition of CCCP
suggested that NorM is a drug/ion antiporter. The specific role
of NorM in FQ resistance was further strengthened by our
observations that inactivation of V. cholerae norM rendered the
strain hypersusceptible to FQs. Efflux of norfloxacin and
ethidium bromide was also impaired in the knockout strain.
The increased expression of norM in some previously described
clinical isolates (1; our unpublished observations) points in the
direction of NorM having a role in FQ resistance in clinical
isolates as well. Whether the inactivation of norM in these
strains lowers the MICs for hydrophilic FQs, however, remains
to be tested.
Phylogenetic analysis of prokaryotic MATE family trans-
porters reveals two subfamilies, with one belonging to the
NorM branch and the other belonging to the DinF branch (7).
Phylogeny-based clustering is likely to determine the substrate
specificity of the MATE family transporters (7). Consistent
with this view, Begum et al. have shown that in V. cholerae,
members of the DinF family are unlikely to be major contrib-
utors to FQ resistance (2). In the complement of MATE family
transporters of V. cholerae, NorM would therefore be pre-
dicted to have a major role in conferring FQ resistance. The
present study has validated this prediction. It is also consistent
with reports from several groups (20, 21, 31) that members of
the NorM family specifically confer resistance to hydrophilic
but not hydrophobic FQs.
The prediction of NorM topology using the online algorithm
HMMTOP 2.0 (35, 36) was validated by fusing C-terminal
truncations of NorM to either the CAT or TEM -lactamase
reporter. The GXFGXP motif, which is conserved in the NorM
family but not in the DinF family, was localized to a periplas-
mic loop between TMS 5 and 6. Deletion of G184KFGAP189
completely abolished NorM activity, as assessed by drug sus-
ceptibility testing, pointing towards a crucial role of this motif
in defining the substrate specificity of NorM. Amino acids
present in large periplasmic loops have also been implicated in
substrate recognition of MexD, a component of the tripartite
MexCD-OprJ pump of P. aeruginosa (14), and in the trimer-
ization of MexB and/or its interaction with MexA (18). Sub-
stitution at G184 led to a loss of activity in each case, except
when G184 was replaced by alanine, indicating that the struc-
tural requirement at this position is very strict. G184 probably
makes a turn which does not leave enough room to tolerate
bulky side chains at this position. Similarly, the loss of activity
in G187 mutants also likely correlates with the extent of desta-
bilization or distortion of the peptide backbone, with the sub-
stitution G1873A having no effect. The contribution of K185
may be due to an intraloop charge-neutralization salt bridge
between K185 and E190, because replacement of either of these
residues with either a neutral or oppositely charged residue
was associated with a loss of activity. Mutation of the glycines
at positions 192 and 195 individually to valine did not confer
any change in the norfloxacin resistance-imparting character of
NorM, indicating that there is likely no turn in the NorM
peptide backbone in this region. The cytoplasmic loop between
TMS 10 and 11 harbors the conserved region L381RGYKD386.
All of the amino acid residues in this region were targeted for
mutagenesis. Y384 alone was found to be required for NorM
activity. Among the three cysteine residues of NorM, only the
replacement of C196 (predicted to be located within the trans-
membrane helix close to the periplasmic loop connecting TMS
5 and 6) with serine had a bearing on activity.
NorM conferred resistance to norfloxacin, ciprofloxacin, and
the cationic substrate ethidium bromide. At physiological pH,
it is expected that the piperazine rings of both ciprofloxacin
and norfloxacin are positively charged (31). This led us to focus
on the role of acidic residues in NorM activity. E124, D155, and
3722 SINGH ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 January 7, 2017 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
E190 were critical for the resistance phenotype of NorM. The
predicted membrane topology (Fig. 2) suggested that E124 and
E190 are located in the periplasmic loops connecting TMS 3
and 4 and TMS 5 and 6, respectively, whereas D155 is located
in the cytoplasmic loop connecting TMS 4 and 5. The impor-
tance of negatively charged residues for the recognition of
cationic drugs was recently demonstrated in a structural study
of Staphylococcus aureus qacR (33). Mazurkiewicz et al. (16)
also demonstrated that acidic residues in both the cytoplasmic
and periplasmic loops are important for the transport of li-
pophilic cationic compounds such as ethidium bromide. Taken
together, these results suggested that removing the positive
charge on the FQ side chain could reduce its export by pumps
such as NorM, thereby improving its efficacy. Our results pro-
vide information on the amino acid residues that are likely
relevant for the binding of these substrates. Further detailed
studies should help in defining the complete set of amino acid
residues likely to be involved in the transport process.
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